Drug insight: An overview of current anticoagulation therapy after heart valve replacement

Nature Clinical Practice Cardiovascular Medicine

Volumn 2, Issue 8, 2005, Pages 415-422

  Hering, Detlef ^a   Piper, Cornelia ^a   Horstkotte, Dieter ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

Anticoagulation; Low molecular weight heparins; Prosthetic heart valve; Vitamin K antagonists

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ANTIVITAMIN K; BLOOD CLOTTING FACTOR 10A INHIBITOR; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; MELAGATRAN; WARFARIN;

ANTICOAGULANT THERAPY; BLEEDING DISORDER; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; COMORBIDITY; CONSENSUS; CORONARY ARTERY DISEASE; DATA ANALYSIS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG WITHDRAWAL; FOLLOW UP; HEART VALVE PROSTHESIS; HEART VALVE REPLACEMENT; HEPARIN INDUCED THROMBOCYTOPENIA; HIGH RISK PATIENT; HUMAN; INTERNATIONAL NORMALIZED RATIO; LONG TERM CARE; LOW DRUG DOSE; MEDICAL DECISION MAKING; MEDICAL EXPERT; OSTEOPOROSIS; PATIENT ATTITUDE; PATIENT COUNSELING; PRACTICE GUIDELINE; PREGNANCY; PRIORITY JOURNAL; PROTECTION; REVIEW; RISK BENEFIT ANALYSIS; RISK FACTOR; STANDARDIZATION; SURGICAL TECHNIQUE; THROMBOEMBOLISM; THROMBOSIS PREVENTION; TREATMENT PLANNING;

ANTICOAGULANTS; AZETIDINES; BENZYLAMINES; GLYCINE; HEART VALVE PROSTHESIS; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; THROMBOEMBOLISM; VITAMIN K;

EID: 23244431810     PISSN: 17434297     EISSN: None     Source Type: Journal    
DOI: 10.1038/ncpcardio0271     Document Type: Review

References (53)

1. Ansell J et al. (2004) The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 (Suppl): S204-S233; erratum Chest 127: 415-416
2. Salem DN et al. (2004) Antithrombotic therapy in valvular heart disease - native and prosthetic. The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 (Suppl): S457-S482
3. Cannegieter SC et al. (1994) Thromboembolic and bleeding complications in patients with mechanical heart valve prostheses. Circulation 89: 635-641
4. Grunkemeier GL and Wu YX (2003) "Our complication rates are lower than theirs": statistical critique of heart valve comparisons. J Thorac Cardiovasc Surg 125: 290-300
5. Devereaux PJ et al. (2001) Differences between perspectives of physicians and patients on anticoagulation in patients with atrial fibrillation: observational study. BMJ 323: 1218-1222
6. Bodnar E (1992) A critical assessment of thrombosis and embolism reporting methods. In Thrombosis, embolism and bleeding, 476-484 (Eds Butchart EG and Bodnar E) ICR Publishers: London
7. Horstkotte D et al. (1993) Unexpected findings concerning thromboembolic complications and anticoagulation after complete ten year follow up of patients with St. Jude Medical Prostheses. J Heart Valve Dis 2: 291-301
8. Horstkotte D et al. (1994) Lower intensity anticoagulation therapy results in lower complication rates with the St. Jude Medical prosthesis. J Thorac Cardiovasc Surg 107: 1136-1145
9. Horstkotte D (1996) Results with mechanical cardiac valvular prostheses. Ann Thorac Surg 62: 1565-1567
10. Horstkotte D (2003) Problems with complication rate analysis. J Thorac Cardiovasc Surg 126: 1668-1670
11. Bodnar E and Horstkotte D (1993) Potential flaws in the assessment of minor cerebrovascular events after heart valve replacement. J Heart Valve Dis 2: 287-290
12. Horstkotte D et al. (2005) Recommendations for reporting morbid events after heart valve surgery. J Heart Valve Dis 14: 1-7
13. Horstkotte D et al. (1993) German Experience with Low Intensity Anticoagulation (GELIA): protocol of a multi-center randomized, prospective study with the St. Jude Medical valve. J Heart Valve Dis 2: 411-419
14. Hering D et al. (2005) Thromboembolic and bleeding complications following St. Jude Medical valve replacement: Results from the German Experience with Low Intensity Anticoagulation study. Chest 127: 53-59
15. Piper C and Horstkotte D (2004) State of the art anticoagulation management. J Heart Valve Dis 13 (Suppl 1): S76-S80
16. van Nooten GJ et al. (2003) Lower-intensity anticoagulation for mechanical heart valves: a new concept with the ATS bileaflet aortic valve. J Heart Valve Dis 12: 495-502
17. van den Besselaar AM (1996) Precision and accuracy of the international normalized ratio in oral anticoagulant control. Haemostasis 26 (Suppl 4): S248-S265
18. Loeliger EA (1992) Therapeutic target values in oral anticoagulation: justification of Dutch policy and a warning against so-called moderate-intensity regimens. Ann Hematol 64: 60-65
19. Chesebro JH et al. (1986) Antithrombotic therapy in patients with valvular heart disease and prosthetic heart valves. J Am Coll Cardiol 8 (Suppl B): S41B-S56B
20. Stein PD and Kantrowitz A (1989) Antithrombotic therapy in mechanical and biological prosthetic heart valves and saphenous vein bypass grafts. Chest 95 (Suppl): S107-S117
21. Saour JH et al. (1990) Trials of different intensities of anticoagulation in patients with prosthetic valves. N Engl J Med 322: 428-432
22. Altman R et al. (1991) Comparison of two levels of anticoagulant therapy in patients with substitute heart valves. J Thorac Cardiovasc Surg 101: 427-431
23. Wilson DB et al. (1991) Low-intensity anticoagulation in mechanical cardiac prosthetic valves. Chest 100: 1553-1557
24. Acar J et al. (1996) AREVA: Multicenter randomized comparison of low-dose versus standard-dose anticoagulation in patients with mechanical prosthetic heart valves. Circulation 94: 2107-2112
25. Meschengieser SS et al. (1997) Low-intensity oral anticoagulation plus low-dose aspirin versus high-intensity oral anticoagulation alone: a randomized trial in patients with mechanical prosthetic heart valves. J Thorac Cardiovasc Surg 113: 910-916
26. Bonow RO et al. (1998) ACC/AHA guidelines for the management of patients with valvular heart disease. A report of the American College of Cardiology/American Heart Association task force on practice guidelines (committee on management of patients with valvular heart disease). J Am Coll Cardiol 32: 1468-1588
27. Horstkotte D (1992) Abnormal cardiac anatomy and physiology. In Thrombosis, embolism and bleeding, 31-69 (Eds Butchart EG and Bodnar E) ICR Publishers: London
28. Schrör K (2001) Combination of oral anticoagulant and platelet inhibitor drugs: focus on the pharmacological aspects of optimizing antithrombotic therapy in mechanical heart valve replacement. Eur Heart J 3 (Suppl Q): S54Q-S59Q
29. Cappelleri JC et al. (1995) Efficacy and safety of combined anticoagulant and antiplatelet therapy versus anticoagulant monotherapy after mechanical heart valve replacement: a meta-analysis. Am Heart J 130: 547-552
30. Hurlen M et al. (2002) Warfarin, aspirin, or both after myocardial infarction. N Engl J Med 347: 969-974
31. van Es RF et al. (2002) Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomised controlled trial. Lancet 360: 109-113
32. Völler H et al. (2001) Home management of anticoagulation. Eur Heart J 3 (Suppl Q): S44Q-S49Q
33. Horstkotte D and Piper C (2004) Improvement of oral anticoagulation therapy by INR self-management. J Heart Valve Dis 13: 335-338
34. Jafri SM (2004) Periprocedural thromboprophylaxis in patients receiving chronic anticoagulation therapy. Am Heart J 147: 3-15
35. Gohlke-Bärwolf C et al. (1995) Guidelines for prevention of thromboembolic events in valvular heart disease. Study Group of the Working Group on Valvular Heart Disease of the European Society of Cardiology. Eur Heart J 16: 1320-1330
36. Kearon C and Hirsh J (1997) Management of anticoagulation before and after elective surgery. N Engl J Med 336: 1506-1511
37. Gohlke-Bärwolf C (2000) Anticoagulation in valvar heart disease: new aspects and management during non-cardiac surgery. Heart 84: 567-572
38. Shapira Y et al. (2001) Anticoagulant management of patients with mechanical prosthetic valves undergoing non-cardiac surgery: indications and unresolved issues. J Heart Valve Dis 10: 380-387
39. Tinker JH and Tarhan S (1978) Discontinuing anticoagulant therapy in surgical patients with cardiac valve prostheses. Observations in 180 operations. JAMA 239: 738-739
40. Katholi RE et al. (1976) Living with prosthetic heart valves. Subsequent noncardiac operations and the risk of thromboembolism or hemorrhage. Am Heart J 92: 162-167
41. Katholi RE et al. (1978) The management of anticoagulation during noncardiac operations in patients with prosthetic heart valves. A prospective study. Am Heart J 96: 163-165
42. Ananthasubramaniam K et al. (2001) How safely and for how long can warfarin therapy be withheld in prosthetic heart valve patients hospitalized with a major hemorrhage? Chest 119: 478-484
43. Aguilar D and Goldhaber SZ (1999) Clinical uses of low-molecular-weight heparins. Chest 115: 1418-1423
44. Hirsh J and Raschke R (2004) Heparin and low-molecular-weight heparin. The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 (Suppl): S188-S203
45. Hering D and Horstkotte D (2003) Role of low-molecular-weight heparins for the anticoagulant treatment of patients with prosthetic heart valves. Dtsch Med Wochenschr 128: 1129-1133
46. Frydman A (1996) Low-molecular-weight heparins: an overview of their pharmacodynamics, pharmacokinetics and metabolism in humans. Haemostasis 26 (Suppl 2): S24-S38
47. Samama MM and Gerotziafas GT (2000) Comparative pharmacokinetics of LMWHs. Semin Thromb Hemost 26 (Suppl 1): S31-S38
48. Montalescot G et al. (2000) Low molecular weight heparin after mechanical heart valve replacement. Circulation 101: 1083-1086
49. Ginsberg JS et al. (2003) Anticoagulation of pregnant women with mechanical heart valves. Arch Intern Med 163: 694-698
50. Bates SM et al. (2004) Use of antithrombotic agents during pregnancy. The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 (Suppl): S627-S644
51. Chan WS et al. (2000) Anticoagulation of pregnant women with mechanical heart valves. A systematic review of the literature. Arch Intern Med 160: 191-196
52. Vitale N et al. (1999) Dose-dependent fetal complications of warfarin in pregnant women with mechanical heart valves. J Am Coll Cardiol 33: 1637-1641
53. Weitz JI et al. (2004) New anticoagulant drugs. The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 (Suppl): S265-S286